OREX Orexigen Therapeutics Inc.

2.12
-0.17  -7%
Previous Close 2.29
Open 2.30
Price To book -0.72
Market Cap 32713648
Shares 15,430,966
Volume 193,680
Short Ratio 35.74
Av. Daily Volume 72,215

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved September 11 2014. CV outcomes trial terminated May 2015. New safety trial CONVENE initiated 2016. Due to be completed January 2022.
Contrave
Obesity

Latest News

  1. Orexigen Therapeutics to Provide Business Update at the 2017 Cantor Fitzgerald Global Healthcare Conference
  2. The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
  3. Why These 4 Biotech Stocks May Not Lose Momentum Soon
  4. ETFs with exposure to Orexigen Therapeutics, Inc. : September 7, 2017
  5. Orexigen Therapeutics to Speak at Upcoming Investor Conferences
  6. Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
  7. Edited Transcript of OREX earnings conference call or presentation 8-Aug-17 9:00pm GMT
  8. Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress
  9. Orexigen reports 2Q loss
  10. Orexigen Therapeutics Announces Second Quarter 2017 Financial Results
  11. Investor Network: Orexigen Therapeutics, Inc. to Host Earnings Call
  12. Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and Austria
  13. Orexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl extended release) to Egypt
  14. Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2017 Financial Results on August 8, 2017
  15. Martin Shkreli made gay investor uncomfortable with sex talk
  16. A Martin Shkreli hedge fund account had 'negative 33 cents' in it when he claimed millions in assets
  17. Investor thought Martin Shkreli was like 'Rain Man' character because of his financial focus
  18. Orexigen Announces Presentation of Data for OREX-1019 and OREX-1038, Preclinical Candidates for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug Addiction
  19. Former officer of Martin Shkreli hedge fund filed SEC complaint against Shkreli while at fund
  20. Former Shkreli employee says 'pharma bro' was deeply depressed after hedge fund 'imploded'